AKROUnknownMid-Cap
Akero Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Akero Therapeutics, Inc. (AKRO), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are AKRO insiders buying or selling?
Akero Therapeutics, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since June 2019, Trabud has recorded 248 Form 4 filings for AKRO: 17 buys ($138.1M) and 231 sells ($249.9M).
Source: SEC EDGAR Form 4
Key Statistics (June 2019 – Oct 15, 2025)
Total Form 4 filings
248
SEC EDGAR
Insider filers
18
Insider buys (17)
$138.1M
Insider sells (231)
$249.9M
Insider sentiment
Net sellingNet insider flow of $111.8M in net selling since June 2019.
Recent AKRO insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 15, 2025 | Andrew Cheng | President and CEO | Sale | 30.0K | $53.98 | $1.6M | SEC ↗ |
| Oct 9, 2025 | Timothy Rolph | Chief Scientific Officer | Sale | 12.5K | $46.08 | $576.0K | SEC ↗ |
| Oct 3, 2025 | Jonathan Young | Chief Operating Officer | Sale | 12.5K | $47.76 | $597.0K | SEC ↗ |
| Sep 13, 2025 | Jonathan Young | Chief Operating Officer | Sale | 586 | $43.02 | $25.2K | SEC ↗ |
| Sep 13, 2025 | Catriona Yale | Chief Development Officer | Sale | 659 | $43.02 | $28.4K | SEC ↗ |
| Sep 13, 2025 | William Richard White | Chief Financial Officer | Sale | 659 | $43.02 | $28.4K | SEC ↗ |
| Sep 13, 2025 | Timothy Rolph | Chief Scientific Officer | Sale | 553 | $43.02 | $23.8K | SEC ↗ |
| Sep 13, 2025 | Andrew Cheng | President and CEO | Sale | 31.8K | $43.23 | $1.4M | SEC ↗ |
| Sep 10, 2025 | Timothy Rolph | Chief Scientific Officer | Sale | 12.5K | $44.17 | $552.1K | SEC ↗ |
| Sep 4, 2025 | Jonathan Young | Chief Operating Officer | Sale | 12.5K | $46.08 | $576.0K | SEC ↗ |
| Aug 13, 2025 | Jonathan Young | Chief Operating Officer | Sale | 12.5K | $47.79 | $597.3K | SEC ↗ |
| Aug 13, 2025 | Andrew Cheng | President and CEO | Sale | 30.0K | $48.59 | $1.5M | SEC ↗ |
| Aug 13, 2025 | Jane Henderson | Director | Sale | 3.0K | $47.46 | $142.4K | SEC ↗ |
| Aug 7, 2025 | Timothy Rolph | Chief Scientific Officer | Sale | 12.5K | $49.30 | $616.3K | SEC ↗ |
| Jul 18, 2025 | Catriona Yale | Chief Development Officer | Sale | 10.0K | $52.95 | $529.5K | SEC ↗ |
| Jul 11, 2025 | Andrew Cheng | President and CEO | Sale | 30.0K | $51.16 | $1.5M | SEC ↗ |
| Jul 9, 2025 | Timothy Rolph | Chief Scientific Officer | Sale | 12.5K | $51.09 | $638.7K | SEC ↗ |
| Jul 3, 2025 | Patrick Lamy | Senior VP, Commercial Strategy | Sale | 2.0K | $52.88 | $105.8K | SEC ↗ |
| Jun 21, 2025 | Andrew Cheng | President and CEO | Sale | 6.6K | $54.84 | $363.0K | SEC ↗ |
| Jun 21, 2025 | Scott A. Gangloff | Chief Technology Officer | Sale | 848 | $54.84 | $46.5K | SEC ↗ |
| Jun 21, 2025 | Patrick Lamy | Senior VP, Commercial Strategy | Sale | 875 | $54.59 | $47.8K | SEC ↗ |
| Jun 21, 2025 | Timothy Rolph | Chief Scientific Officer | Sale | 1.1K | $54.84 | $61.9K | SEC ↗ |
| Jun 21, 2025 | William Richard White | Chief Financial Officer | Sale | 1.6K | $54.84 | $89.6K | SEC ↗ |
| Jun 21, 2025 | Catriona Yale | Chief Development Officer | Sale | 1.6K | $54.84 | $89.6K | SEC ↗ |
| Jun 21, 2025 | Jonathan Young | Chief Operating Officer | Sale | 1.5K | $54.84 | $79.7K | SEC ↗ |
Showing the 25 most recent of 248 Form 4 filings for Akero Therapeutics, Inc..
Most active AKRO insiders
- Andrew Cheng46 filings
- Jonathan Young42 filings
- Catriona Yale40 filings
- Timothy Rolph31 filings
- William Richard White28 filings
Ask anything about AKRO insider activity
Use Trabud's AI agent to query Akero Therapeutics, Inc.'s Form 4 history in plain English — "Show me AKRO CEO purchases this year" or compare it against any other ticker.
Open the AI agentAKRO insider trading FAQ
Are Akero Therapeutics, Inc. insiders buying or selling?
Akero Therapeutics, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since June 2019, Trabud has recorded 248 Form 4 filings for AKRO: 17 buys ($138.1M) and 231 sells ($249.9M). Over the full record that is net selling of $111.8M.
How many insiders trade AKRO stock?
18 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Akero Therapeutics, Inc.. The most recent filing was accepted on Oct 15, 2025.
Where does Trabud get AKRO insider trading data?
All AKRO insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.